cladribine has been researched along with Devic Disease in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Brod, SA | 1 |
| Papuć, E; Rejdak, K | 1 |
| Buc, M | 1 |
2 review(s) available for cladribine and Devic Disease
| Article | Year |
|---|---|
The genealogy, methodology, similarities and differences of immune reconstitution therapies for multiple sclerosis and neuromyelitis optica.
Topics: Alemtuzumab; Antineoplastic Agents, Immunological; Cladribine; Humans; Immune Reconstitution; Multiple Sclerosis; Neuromyelitis Optica | 2022 |
New biological agents in the treatment of multiple sclerosis.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Products; Cladribine; Daclizumab; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunoglobulin G; Immunologic Factors; Immunosuppressive Agents; Indans; Multiple Sclerosis; Natalizumab; Neuromyelitis Optica; Oxadiazoles; Rituximab | 2018 |
1 other study(ies) available for cladribine and Devic Disease
| Article | Year |
|---|---|
Cladribine suppresses disease activity in neuromyelitis optica spectrum disorder: a 2-year follow-up study.
Topics: Cladribine; Follow-Up Studies; Humans; Neuromyelitis Optica; Retrospective Studies; Treatment Outcome | 2021 |